- Volpara’s US customers will get access to Natera’s comprehensive genetic testing services within Volpara’s software workflow.
- Volpara plans to create a fully integrated ordering process for Natera genetic testing services within the Volpara® Breast Health PlatformTM.
- As part of the agreement, Volpara has the potential to offer increased value to mutual customers upon successful clinical implementation.
Health technology software provider Volpara Health Technologies Limited (ASX:VHT) shared today that it will be collaborating with leading genetics company Natera.
Natera is a NASDAQ-listed global leader in cellfree DNA testing with a market cap in excess of US$10 billion.
The collaboration is to bring Natera’s Empower Hereditary Cancer Test to Volpara’s customers in the United States.
As per the release, Volpara will integrate Natera’s Empower Hereditary Cancer Test into Volpara’s software workflow to create additional access for women to comprehensive genetic testing services in different clinical settings.
It should be noted that at least one Volpara software product is used with over 33% of women who attend screening each year in the United States. Customers use Volpara’s breast cancer risk assessment software to confidently make informed decisions for triaging patients to supplemental imaging and genetic testing.
Risk assessment is also required by many US insurance companies before additional testing. Along with supplemental screening, such as ultrasound and MRI, genetic testing assists in earlier cancer detection and is critical in reducing treatment costs and increasing the chances of survival.
Natera will allow Volpara to continue driving the adoption of personalised breast screening in the United States. Natera will also compliment VHT’s interest in its risk offerings and the ability to direct women to the appropriate genetic testing at the right time.